A. Sinclair Dunlop
Sinclair has over 20 years of experience successfully building early-stage life science companies and delivering competitive returns to international investors.
Prior to co-founding Epidarex, Sinclair founded and was Managing Partner of MASA Life Science Ventures, LP (MLSV) an early-stage venture fund that successfully built an international portfolio of leading life science and health technology companies. Sinclair has venture investing experience in the U.S., Europe, East Asia and Canada and has built an international network of blue-chip investors from both the public and private sectors.
He currently serves on the Boards of Directors of Apellis Pharmaceuticals Inc. (NASDAQ: APLS), Clyde Biosciences Ltd. and Lario Therapeutics Ltd.
Sinclair received his M.B.A. from Columbia Business School where he was the R.C. Kopf British-American Fellow in International Business. He holds an M.A. with Honours in Political Economy from the University of Glasgow and an M.A. in International Relations from the Maxwell School of Citizenship and Public Affairs at Syracuse University. Sinclair is a St. Andrew’s Society of New York Scholar. Earlier in his career, he was a political economist with the Center for Strategic and International Studies in Washington, D.C.
He currently serves as the Chairman of Inspiring Scotland, one of the UK’s largest venture philanthropy charities.